Twist Bioscience Expands Expert Custom Alliance Panel Offering
October 05, 2021 at 08:00 AM EDT
- Ready to Order Clinically Validated, Expert-Designed Panels Offer Important Tools for Multiple Research Applications –
- Twist Alliance Pan-Cancer Methylation Panel Launched -
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced an expansion of its expert-led Alliance Panel product offering. Designed through collaboration with world-leading experts, Twist Alliance Panels combine validated content with Twist next-generation sequencing (NGS) workflow, target enrichment and DNA probes. In an extension of Twist’s OEM strategy, Twist will market products designed by key opinion leaders in a wide range of clinical applications and powered by Twist tools through the Alliance Panel program. In return, expert collaborators receive a royalty on the sale of products and will carry partner branding.
“Data generated and validated by experts around the world bring incredible value to the research community,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “By working together, we are leveraging this extensive knowledge, providing the global community with better research tools, all powered by Twist products, and also ensuring the experts involved receive recognition and royalties for their hard work.”
As the first Alliance Panel offering, Twist collaborated with the Regeneron Genetics Center LLC (RGC), a wholly-owned subsidiary of Regeneron, to develop the Twist Diversity SNP Panel, a custom NGS population genetics genotyping assay available to researchers globally for population genomics studies.
Today, Twist and AnchorDx launched the Twist Alliance Pan-cancer Methylation Panel based on The Cancer Genome Atlas (TCGA) database, including 31 cancer types and 47 TCGA database disease entities. The pan-cancer profile saves customers sequencing costs and reduces the complexity of analysis. Validation studies were conducted using tumor biopsy samples from breast cancer, colorectal cancer and non-small cell lung cancer. DNA methylation regions included in the panel have been found to clearly differentiate cancer tissues from the non-malignant tissue in these three cancer types, among the most common cancers.
About Twist Alliance Panels
In partnership with leading research institutions from around the world, Twist has curated a collection of high-quality target enrichment panels for applications ranging from carrier screening to cancer diagnostics and whole exome sequencing. The Twist Alliance Panels combine the strengths of precise, highly uniform oligonucleotide synthesis with the specialty expertise of leading scientific research partners.
Well designed, custom target enrichment panels enable increased sequencing depth on target genes while reducing overall sequencing. This allows for more sensitive detection of target sequences and higher confidence variant detection.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; the retention of employees of acquired companies and the ability of Twist Bioscience to successfully integrate acquired companies and to achieve expected benefits, risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Quarterly Report Form 10-Q filed with the Securities and Exchange Commission on August 9, 2021 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.